Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP66213.RAevPPYgBL1d6c32xK2g9GMIrQeksdvpuGQuImQkEotLo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP66213.RAevPPYgBL1d6c32xK2g9GMIrQeksdvpuGQuImQkEotLo130_assertion type Assertion NP66213.RAevPPYgBL1d6c32xK2g9GMIrQeksdvpuGQuImQkEotLo130_head.
- NP66213.RAevPPYgBL1d6c32xK2g9GMIrQeksdvpuGQuImQkEotLo130_assertion description "[BRAF genotype is correlated with PFS and OS in KRAS wild type mCRC patients, which is independent of cetuximab treatment. PIK3CA mutation, loss of PTEN expression, EGFR GCN and HER2 GCN have no predictive value for response to treatment with cetuximab, neither individually nor in combination with other markers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP66213.RAevPPYgBL1d6c32xK2g9GMIrQeksdvpuGQuImQkEotLo130_provenance.
- NP66213.RAevPPYgBL1d6c32xK2g9GMIrQeksdvpuGQuImQkEotLo130_assertion evidence source_evidence_literature NP66213.RAevPPYgBL1d6c32xK2g9GMIrQeksdvpuGQuImQkEotLo130_provenance.
- NP66213.RAevPPYgBL1d6c32xK2g9GMIrQeksdvpuGQuImQkEotLo130_assertion SIO_000772 20413299 NP66213.RAevPPYgBL1d6c32xK2g9GMIrQeksdvpuGQuImQkEotLo130_provenance.
- NP66213.RAevPPYgBL1d6c32xK2g9GMIrQeksdvpuGQuImQkEotLo130_assertion wasDerivedFrom gad-20130706 NP66213.RAevPPYgBL1d6c32xK2g9GMIrQeksdvpuGQuImQkEotLo130_provenance.
- NP66213.RAevPPYgBL1d6c32xK2g9GMIrQeksdvpuGQuImQkEotLo130_assertion wasGeneratedBy ECO_0000203 NP66213.RAevPPYgBL1d6c32xK2g9GMIrQeksdvpuGQuImQkEotLo130_provenance.